Miles Carroll
Miles Carroll
HOST-PATHOGEN INTERACTIONS OF HIGH CONSEQUENCE EMERGING VIRUSES
Our work centres around high consequence emerging viral infections. Currently, our focus is on Ebola, Lassa fever and SARS-CoV-2. We are interested in host-pathogen interactions, development of anti-virals and recently we have been looking at the IgG response following SARS-CoV-2 infection and/or vaccination in humans and animal models. To further support this work we are using a live virus neutralisation, multiplex immunoassays and novel ACE2 inhibition assay to inform on the ability of serum to neutralise SARS-CoV-2 variants of concern (VOC). We are also interested in the innate response to viral infection, particularly activation and/or evasion of the complement system
Recent publications
-
Nipah Virus Therapeutics: A Systematic Review to Support Prioritisation for Clinical Trials
Preprint
Chan XHS. et al, (2024)
-
Direct enhancement of viral neutralising antibody potency by the complement system: a largely forgotten phenomenon.
Journal article
Mellors J. and Carroll M., (2024), Cell Mol Life Sci, 81
-
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials.
Journal article
Voysey M. et al, (2021), Lancet, 397, 881 - 891